Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses
06 Avril 2022 - 1:30PM
Business Wire
Agreement extends current licensing and
collaboration agreement to include rapid production of intranasal
vaccine candidates against future variants
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) today announced it has extended a licensing and
collaboration agreement with the National Research Council of
Canada (NRC) that enables Oragenics to pursue an intranasal vaccine
designed to protect against future variants of coronaviruses. The
NRC cell expression technologies provide Oragenics with a platform
that can generate cell lines for high-yield production of spike
protein antigens for existing and emerging variants of concern.
This platform could allow production of cell lines within six to
eight weeks of spike gene sequence availability, compared with six
to nine months for traditional production of such cell lines. The
NRC technologies, developed with support from the NRC’s Pandemic
Response Challenge program, will expedite the evaluation of future
intranasal vaccine candidates in preclinical and clinical
studies.
“Oragenics is well-positioned to develop intranasal vaccines
against future variants of SARS-CoV-2 thanks to our successful,
on-going collaboration with the NRC,” said Frederick W. Telling,
Ph.D., Oragenics’ Executive Chairman. “We had anticipated the need
for rapid development of COVID-19 vaccine candidates against new
variants and can leverage the NRC cell expression platform to
address future variants.”
Oragenics recently demonstrated the protection of hamsters
against SARS-CoV-2 with the intranasal NT-CoV2-1 vaccine candidate,
which strongly supports the further development into an
IND-enabling GLP toxicology study and a first-in-human Phase 1
clinical study.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is NT-CoV2-1, an
intranasal vaccine candidate to prevent COVID-19 and variants of
the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus
spike protein research licensed from the NIH and the NRC with a
focus on reducing viral transmission and offering a more
patient-friendly intranasal administration. Its lantibiotics
program features a novel class of antibiotics against bacteria that
have developed resistance to commercial antibiotics. For more
information about Oragenics, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, the following: the Company’s ability to advance the
development of its vaccine candidate and lantibiotics candidate
under the timelines and in accord with the milestones it projects;
the Company’s ability to obtain funding, non-dilutive or otherwise,
for the development of the vaccine and lantibiotic product
candidates, whether through its own cash on hand, or another
alternative source; the regulatory application process, research
and development stages, and future clinical data and analysis
relating to vaccines and lantibiotics, including any meetings,
decisions by regulatory authorities, such as the FDA and
investigational review boards, whether favorable or unfavorable;
the potential application of our vaccine candidate to variants and
other coronaviruses; the Company’s ability to obtain, maintain and
enforce necessary patent and other intellectual property
protection; the nature of competition and development relating to
COVID-19 immunization and therapeutic treatments and demand for
vaccines and antibiotics; the Company’s expectations as to
administration, manufacturing, storage and distribution; other
potential adverse impacts due to the global COVID-19 pandemic, such
as delays in regulatory review, interruptions to manufacturers and
supply chains, adverse impacts on healthcare systems and disruption
of the global economy; and general economic and market conditions
and risks, as well as other uncertainties described in our filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220406005472/en/
Oragenics, Inc. Michael Sullivan, Chief Financial Officer
813-286-7900 msullivan@oragenics.com
Or
LHA Investor Relations Tirth T. Patel 212-201-6614
tpatel@lhai.com
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024